Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT)Status: open
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma
Treatment for Hodgkin´s Lymphoma
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant
SponsorsThis trial is sponsored by Bristol-Myers Squibb.
Interested in Clinical Trial?
Providers Associated With This Trial
- Sachin Pai, MBBS, M.D.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology